亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Radiomics-clinical nomogram for response to chemotherapy in synchronous liver metastasis of colorectal cancer: Good, but not good enough

        2022-12-06 12:11:47HanYanTuNanYu
        World Journal of Gastroenterology 2022年9期

        Han Yan,Tu-Nan Yu

        Abstract There remains a persistent unmet need to detect the disease nonresponse (nonDR)subgroup before adjuvant therapy in synchronous liver metastasis patients with colorectal cancer. Ma’s radiomics-clinical nomogram shows potential for the early detection of nonDR subgroups, but it is not good enough owing to at least three limitaions, which we address in this letter to the editor. First, the study did not explore RAS/BRAF mutations, HER2 amplifications, etc. to complement the current nomogram. Second, the nomogram was not validated in left- and rightsided tumors separately. Third, the most critical factor for determining the success of adjuvant therapy should be resectability rather than tumor size shrinkage,which was used in the study.

        Key Words: Synchronous liver metastasis; Colorectal cancer; Radiomics

        TO THE EDITOR

        Maet al[1] recently published a novel study investigating the effect of magnetic resonance imagingradiomics in predicting chemotherapeutic response in synchronous liver metastasis (SLM) patients with colorectal cancer (CRC). They proposed a radiomics-clinical nomogram (including the radiomics score,CA19-9, and lymphatic staging) with an area under the curve of 0.809, suggesting high predictive accuracy.

        We congratulate the authors for their creative work, as in decision-making for adjuvant therapy in CRC patients with unresectable SLM, there remains a persistent unmet need to detect the disease nonresponse (nonDR) subgroup. Early detection of nonDR patients, aided by the radiomics-clinical nomogram of Ma’s study, could result in substantial changes in subsequent therapeutic plans. For instance, in nonDR cases, more aggressive regimens could be applied instead of the frequently used FOLFOX or CAPOX, such as administration of bevacizumab to inhibit vascular endothelial growth factor or pembrolizumab for immunotherapy. Local regional therapies, including radiofrequency ablation and transcatheter arterial chemoembolization,could also be considered to treat SLM.

        However, despite the aforementioned merit, there are at least three limitations to be discussed concerning this nomogram. First, although the authors explored tumor biomarkers, including CEA and CA19-9, to complement radiomics, the statuses of some critical tumor genes (e.g., RAS/BRAF mutations,HER2 amplification, and MSI/MMR status) were not examined, despite the relevant recommendation in the latest National Comprehensive Cancer Network guideline[2]. Second, it is noteworthy that the biological behaviors of CRC differed depending on the anatomical location[3]. For instance, right-sided CRC patients with SLM were unlikely to respond to cetuximab and panitumumab as first-line therapy.Therefore, the performance of Ma’s nomogram should be validated in right- and left-sided CRC separately. Last but not least, the most critical limitation was that the success of adjuvant therapy in CRC patients with SLM should be resectability, rather than tumor size shrinkage used in this study.

        In conclusion, in CRC patients with SLM, Ma’s radiomics-clinical nomogram shows potential for clinical utilization. However, it is currently not good enough.

        FOOTNOTES

        Author contributions:All authors helped to prepare this manuscript; Yan H and Yu TN contributed to manuscript writing, drafting conception and design.

        Conflict-of-interest statement:All authors declare that there are no conflicts of interest, and there was no fund

        supporting this manuscript.

        Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

        Country/Territory of origin:China

        ORCID number:Han Yan 0000-0001-8189-6678; Tu-Nan Yu 0000-0003-0866-3178.

        S-Editor:Gong ZM

        L-Editor:A

        P-Editor:Gong ZM

        国产乱妇乱子视频在播放| 伊人久久大香线蕉av五月| 日韩人妻少妇一区二区三区| 国产真实夫妇交换视频| AV无码中文字幕不卡一二三区| 啪啪视频免费看一区二区| 亚洲色欲色欲大片WWW无码| 国产熟女露脸大叫高潮| 日日碰狠狠添天天爽超碰97久久| 久久99久久99精品中文字幕| 五月婷婷激情综合| 一个人看的在线播放视频| 99久久精品在线视频| 国产免费人成视频在线观看| 综合网在线视频| 午夜一区二区在线视频| 丰满女人猛烈进入视频免费网站| 亚洲成a v人片在线观看| 小12箩利洗澡无码视频网站| 美女人妻中文字幕av| 揄拍成人国产精品视频| 伊人狠狠色丁香婷婷综合| 久久久久久国产精品美女| 国产av一区二区三区区别| 不卡av一区二区在线| 亚洲爆乳无码专区www| 亚洲不卡中文字幕无码| 日日噜噜夜夜狠狠久久av| 日本精品免费看99久久| 欧美成人在线视频| 九九精品无码专区免费| 偷拍美女一区二区三区视频| 国产自国产自愉自愉免费24区| 欧美熟妇色ⅹxxx欧美妇| 96精品在线| 热综合一本伊人久久精品| 久久不见久久见免费视频6| 日本乱子人伦在线视频| 丰满少妇人妻无码超清| 人妻少妇精品专区性色anvn| 国产精品51麻豆cm传媒|